Resverlogix Corp. (RVX.TO) Research

Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.

Market snapshot

Symbol
RVX.TO
Price
$0.09
Day change
-10.00%
Market cap
$20.1M
P/E ratio
-2.93x
52-week range
0.04-0.3
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Avicanna Inc. (AVCN.TO)
  • BriaCell Therapeutics Corp. (BCT.TO)
  • Rapid Dose Therapeutics Corp. (DOSE.CN)
  • Gemina Laboratories Ltd. (GLAB.CN)
  • Hemostemix Inc. (HEM.V)
  • MediPharm Labs Corp. (LABS.TO)
  • Microbix Biosystems Inc. (MBX.TO)
  • Pangenomic Health Inc. (NARA.CN)

Open Resverlogix Corp. (RVX.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.